RxDoctor Payments Data

Steven Nabers, DO

Family Medicine · Red Bay, ALNPI 1568924900

Payments from drug & device makers

$822in general payments, 2019–2025

Across 31 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$625
  • AstraZeneca$108
  • Organon$48
  • Lilly USA, LLC$19
  • Boehringer Ingelheim$18
  • Phathom Pharmaceuticals, Inc.$4

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$822 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$501,126
Medicare patients
286
Services billed
2,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$41,765
JardianceEmpagliflozin45$27,605
OzempicSemaglutide16$19,304
MounjaroTirzepatide18$18,864
FarxigaDapagliflozin Propanediol22$14,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,384
JanuviaSitagliptin Phosphate17$10,061
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,599
Tresiba Flextouch U-100Insulin Degludec14$7,576
Fesoterodine Fumarate ErFesoterodine Fumarate13$2,392
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,369
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,773
Metoprolol Succinate86$1,566
Albuterol Sulfate HfaAlbuterol Sulfate62$1,307
Fluconazole82$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$27,60545 claims
AstraZenecaFarxiga, Breztri Aerosphere$108$22,17434 claims
Lilly USA, LLCMounjaro$19$18,86418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Red Bay

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →